Clorpromazina

證據等級: L5

預測適應症: 0 個

Clorpromazina: Repurposing Evaluation Incomplete — TxGNN Predictions Not Available

One-Sentence Summary

Clorpromazina (chlorpromazine) is a first-generation phenothiazine antipsychotic with established use in psychiatric conditions. However, this Evidence Pack contains no TxGNN-predicted new indications and is missing critical fields — original indications, mechanism of action, and safety data — making a full repurposing evaluation impossible at this time. The data pipeline has confirmed that DrugBank and package insert sources each returned one result, but their content was not yet integrated into the Evidence Pack.

Quick Overview

Item	Content
Original Indication	Not available in Evidence Pack
Predicted New Indication	None — TxGNN predictions not populated
TxGNN Prediction Score	N/A
Evidence Level	N/A
Italy Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack for Clorpromazina is critically incomplete — without TxGNN predictions, original indications, mechanism of action, or safety data, no repurposing hypothesis can be formed or evaluated.

To proceed, the following is needed:

TxGNN model output — predicted_indications array is empty; the model must be run or results loaded for this drug before any evaluation can begin
Original approved indications — original_indications is empty; retrieve from AIFA database or package insert
Mechanism of action — DrugBank query returned 1 result on 2026-03-29 but the data was not integrated into drug.original_moa; extract and populate
Safety information — Package insert query returned 1 result on 2026-03-29 but key_warnings and contraindications remain unpopulated; parse and integrate
Drug interaction data — DDI query returned no results; consider querying an alternative DDI database (e.g., DrugBank interactions, Drugs.com)
Italy market verification — Confirm whether Clorpromazina holds any AIFA authorizations; 0 licenses is unexpected for a compound in this class
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.